Results 61 to 70 of about 5,049,707 (331)

Scientific Opinion on the update of the list of QPS‐recommended biological agents intentionally added to food or feed as notified to EFSA

open access: yesEFSA journal. European Food Safety Authority, 2017
EFSA is requested to assess the safety of a broad range of biological agents in the context of notification for market authorisation as sources of food and feed additives, food enzymes and plant protection products.
A. Ricci   +35 more
semanticscholar   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham   +21 more
wiley   +1 more source

Opinion dynamics and synchronization in a network of scientific collaborations

open access: yes, 2006
In this paper we discuss opinion dynamics in the Opinion Changing Rate (OCR) model, recently proposed (A.Pluchino, V.Latora and A.Rapisarda Int. J. Mod. Phys. C, 16, No.4, 515-531 (2005)).
Albert   +27 more
core   +1 more source

Carbon pricing – perceived strengths, weaknesses and knowledge gaps according to a global expert survey

open access: yesEnvironmental Research Letters
Researchers from different disciplines have different opinions about carbon pricing. To better understand the reasoning behind these perspectives, we utilize responses to three open-ended questions from a global survey among almost 800 researchers from a
Ivan Savin   +2 more
doaj   +1 more source

The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis

open access: yesPLoS Neglected Tropical Diseases, 2019
1 Office of Anti-infectives and Vaccines, Human Medicines Evaluation Division, European Medicines Agency (EMA), Amsterdam, The Netherlands, 2 International Affairs Division, European Medicines Agency (EMA), Amsterdam, The Netherlands, 3 Clinical ...
E. Pelfrene   +6 more
semanticscholar   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

open access: yesMolecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts   +8 more
wiley   +1 more source

The Truth About Soviet Whaling [PDF]

open access: yes, 2008
I have always condemned (and to do anything more was not within our power or abilities) the illegal and sometimes destructive whaling by the Soviet Union.
Berzin, Alfred A.
core  

Optimizing Guideline-Recommended Antibiotic Doses for Pediatric Infective Endocarditis [PDF]

open access: yes, 2016
The American Heart Association recently published an updated scientific statement on the management of infective endocarditis in childhood. The recommendations included for vancomycin, aminoglycoside, and β-lactam dosing and monitoring are based ...
Israel, Emily N.   +3 more
core   +3 more sources

Scientific Opinion addressing the state of the science on risk assessment of plant protection products for in‐soil organisms

open access: yesEFSA journal. European Food Safety Authority, 2017
Following a request from EFSA, the Panel on Plant Protection Products and their Residues developed an opinion on the science behind the risk assessment of plant protection products for in‐soil organisms.
C. Ockleford   +27 more
semanticscholar   +1 more source

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

open access: yesMolecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy